Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements

Rhea-AI Summary

Intelligent Bio Solutions (NASDAQ: INBS) reported strong fiscal Q3 2025 results, with 20% sequential quarterly revenue growth to $0.73 million and 91% year-over-year quarterly gross profit growth to $341,368. The company's high-margin cartridge sales now represent 58% of total revenue for the nine months ended March 31, 2025. INBS expanded its customer base by 35 new accounts, bringing total active accounts to over 450. The company enhanced its global presence through partnerships in Spain, Andorra, Europe, and the Middle East, while securing its sixth U.S. patent for the Intelligent Fingerprinting Drug Screening Cartridge. Financial highlights include total cash of $2.81 million, shareholders equity of $4.94 million, and a reduced net loss of $2.54 million. The company also launched multilingual functionality and expanded marketing initiatives across key regions.

Positive

• 20% sequential quarterly revenue growth to $0.73 million
• 91% year-over-year quarterly gross profit growth to $341,368
• High-margin cartridge sales increased to 58% of total revenue
• Addition of 35 new accounts, reaching over 450 total active accounts
• Secured sixth U.S. patent for drug screening cartridge
• Reduced net loss by $434,141 compared to previous year
• Enhanced production capacity leading to reduced costs

Negative

• Total revenue for nine months ($2.21M) decreased compared to same period in 2024 ($2.38M)
• Still operating at a significant net loss of $2.54 million

Insights

Financial Analyst

Intelligent Bio Solutions shows improving financials with 20% QoQ revenue growth and 91% YoY gross profit growth, driven by higher-margin recurring cartridge sales.

Intelligent Bio Solutions' fiscal Q3 2025 results reveal encouraging financial trends despite continued net losses. The company delivered $0.73 million in quarterly revenue, representing a 20% sequential increase from Q2, though this was lower than the $0.82 million reported in the same quarter last year. More impressive is the 91% year-over-year improvement in gross profit to $341,368, indicating significant operational efficiencies.

The shift toward recurring cartridge sales is a crucial strategic development. Cartridges now represent 58% of total revenue for the nine months ended March 31, 2025, up 9% from the same period in 2024. This transition toward consumables is strengthening INBS's recurring revenue model and expanding margins, following the classic "razor and blade" business approach seen in diagnostic companies.

While total nine-month revenue slightly declined to $2.21 million compared to $2.38 million in the same period last year, the company's emphasis on higher-margin products has substantially improved profitability metrics. The company cites enhanced production capacity reducing costs across labor, materials, and overhead.

The narrowing net loss (down by $434,141 to $2.54 million for the quarter) signals improving operational efficiency. With $2.81 million in cash and $4.94 million in shareholders' equity as of March 31, 2025, the company appears to have sufficient runway to continue its growth strategy while working toward profitability.

The expansion of the customer base by 35 new accounts (bringing total active accounts to over 450) demonstrates market acceptance and potential for future growth, particularly as the company pursues international expansion ahead of its planned U.S. market entry.

Medical Technology Expert

INBS is solidifying its global footprint in drug screening through multilingual platform development, international partnerships, and intellectual property protection.

Intelligent Bio Solutions is executing a methodical global expansion strategy for its fingerprint-based drug testing technology. The company's focus on multilingual implementation is particularly strategic—adding Arabic, Spanish, and Italian interfaces to both their screening system and web presence eliminates critical barriers to adoption across Europe, the Middle East, and Latin America.

The company's intellectual property position has strengthened with the granting of its sixth U.S. patent specific to the Intelligent Fingerprinting Drug Screening Cartridge. This patent protection is crucial for maintaining competitive advantage in the non-invasive testing market and likely increases the technology's valuation ahead of potential U.S. market entry.

INBS is pursuing a two-pronged market development approach through both direct customer acquisition and distributor partnerships. New collaborations with Detecto in Spain/Andorra and IVY Diagnostics across Europe/Middle East extend the company's reach without requiring massive internal sales team expansion. This capital-efficient approach enables faster geographic penetration while leveraging local market expertise.

The ongoing regulatory scoping in Canada, Indonesia, and the Philippines indicates a strategic approach to market prioritization, focusing on regions with favorable regulatory environments while preparing for longer-term opportunities. The company's participation in six key industry events across multiple continents demonstrates commitment to building awareness among potential enterprise customers and distributors.

With fingerprint-based testing offering advantages in simplicity, non-invasiveness, and immediate results compared to traditional urine or blood testing, INBS appears well-positioned to capture market share in safety-critical industries where regular drug screening is essential. The growth in cartridge sales as a percentage of revenue validates that customers are actively using the technology rather than merely piloting it.

20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth

Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025 

35 new accounts and international growth during Q3 bring total active accounts to over 450

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2025, and provided a business update.  

The Company delivered a strong quarter of growth in revenue compared to the previous quarter, supported by ongoing expansion across safety-critical industries and steady customer acquisition. Cartridge sales, a key contributor to margin improvement, continue to make up a growing share of income, contributing 58% of total revenue for the fiscal year to March 31, 2025, and strengthening the Company’s recurring revenue model. With 35 new customers added during the quarter and an active customer base now surpassing 450 accounts, INBS remains on track with its plans to scale its commercial footprint and international presence ahead of its expected entry into the U.S. market.

During the fiscal third quarter, the Company advanced its international growth strategy and product readiness through a series of targeted initiatives. These included expanded access in key European markets, multilingual upgrades to its drug screening system and digital outlets, and further protection of its core intellectual property portfolio. Together, we believe these developments support the Company’s ability to scale globally and drive sustained commercial growth.

“As we expand further into new markets, our focus on growing cartridge adoption, our highest-margin revenue stream, is strengthening the business fundamentals,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “We’ve also seen a notable reduction in losses this quarter, reflecting ongoing improvements in cost control and operational efficiency. To support global scalability, we introduced multilingual functionality across our drug screening system and websites, ensuring our solution is widely accessible, commercially viable, and ready for broader distribution across international markets. We believe these efforts are laying a strong foundation for long-term, sustainable revenue growth.”

Marketing Updates: Scaling Awareness and Engagement

• Launched localized websites in Arabic, Spanish, and Italian as part of a broader localization strategy to support lead generation and improve accessibility across key regions.
• Activated multi-channel advertising campaigns in the UK and Australia, targeting safety-critical industries.
• Launched dedicated distributor-focused campaigns to attract new channel partners across the Asia Pacific region, Europe, and the Middle East.
• Showcased the Intelligent Fingerprinting Drug Testing Solution at six key events:
  • United Kingdom: The Port Skills & Safety Event and the Health & Safety Event in the UK;
  • United States: The National Drug and Alcohol Screening Association (NDASA) Conference and iAccess events in the USA; and
  • Europe: The European Workplace Drug Testing Society (EWDTS) Conference and Police Winter Forum in Europe.
    

Sales Updates: Expanding Global Pipeline

• Secured 35 new accounts throughout the quarter ended March 31, 2025, bringing the Company's total active account base to over 450.
• Expanded access to fingerprint drug testing in Spain and Andorra through a strategic collaboration with Detecto, a division of Spanish distributor MTB Distribuciones Tecnologicas SL.  
• Strengthened foothold throughout Europe and the Middle East through partnership with IVY Diagnostics Srl.
  

Regulatory and Product Development: Progress Across Key Markets

• Granted a patent in the United States relating to the Intelligent Fingerprinting Drug Screening Cartridge, marking the Company's sixth U.S. patent.
• Announced plans for a major system upgrade to support multiple global languages across North and South America, Europe, Asia Pacific, and the Middle East.
• Integrated Arabic and Latin American Spanish to the Intelligent Fingerprinting Drug Screening System as part of the Company's multilingual upgrade.  
• Continued regulatory scoping in Canada, Indonesia, and the Philippines to support long-term expansion strategy.

Financial Results for the Fiscal 2025 Third Quarter and Nine-Months Ended March 31, 2025: 

• Total cash and cash equivalents on hand as of March 31, 2025, was $2.81 million. 
• Shareholders equity as of March 31, 2025, was $4.94 million. 
• Total revenues for the fiscal third quarter were $0.73 million, an increase of 20% quarter-over-quarter. 
• Gross profits for the fiscal third quarter were $341,368, an increase of 91% year-over-year.
• Cartridge revenue increased from 49% to 58% for the nine months ended March 31, 2025, an increase of 9 percentage points compared to the same period in 2024.
• Total revenue for the nine months ended March 31, 2025, was $2.21 million. 

Revenue from sales of goods for the three months ended March 31, 2025, increased by $121,373, or 20%, to $728,867 from $607,494, compared to three months ended December 31, 2024, and compares to $823,800 for the three months ended March 31, 2024. Total revenue for the nine months ended March 31, 2025, was $2.21 million compared to $2.38 million for the same period in 2024. Gross profit increased by $162,879, or 91%, to $341,368 from $178,489 for the three months ended March 31, 2025, compared to the same period in 2024, and increased by $301,214 or 49% to $911,282 from $610,068 for the nine months ended March 31, 2025. Increases in gross profit are mainly attributable to enhanced production capacity, which has reduced direct labor, direct materials, and direct product-related overhead costs. The Company continues to improve its strategic sales mix and operational streamlining, thus driving increased gross profit. Net loss attributable to the Company decreased by $434,141 to $2,543,526 from $2,977,667 for the three months ended March 31, 2025, compared to the same period in 2024.

About Intelligent Bio Solutions Inc.   

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

For more information, visit: https://www.ibs.inc/ 

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:   
Intelligent Bio Solutions Inc.  
info@ibs.inc   
LinkedIn | Twitter  

Investor & Media Contact:  
Valter Pinto, Managing Director  
KCSA Strategic Communications  
PH: (212) 896-1254  
INBS@kcsa.com

(Financial tables to follow)

Intelligent Bio Solutions Inc.
Condensed Consolidated Balance Sheets
(Amount in US$)

		As of				As of
		March 31, 2025				June 30, 2024
		(Unaudited)
ASSETS
Current assets
Cash and cash equivalents		$	2,807,112			$	6,304,098
Accounts receivable, net			510,963				429,704
Inventories, net			683,488				777,537
Research and development tax incentive receivable			520,312				525,332
Other current assets			585,456				497,572
Total current assets			5,107,331				8,534,243
Property and equipment, net			546,458				565,850
Operating lease right-of-use assets			126,798				306,744
Intangibles, net			3,803,940				4,372,026
Total assets		$	9,584,527			$	13,778,863
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued expenses		$	1,330,556			$	1,704,568
Current portion of operating lease liabilities			151,322				274,834
Current portion of deferred grant income			2,278,681				2,486,668
Current employee benefit liabilities			447,670				469,381
Current portion of notes payable			356,156				515,282
Total current liabilities			4,564,385				5,450,733
Employee benefit liabilities, less current portion			72,672				63,615
Operating lease liabilities, less current portion			3,704				81,324
Total liabilities			4,640,761				5,595,672
Commitments and contingencies
Shareholders’ equity
Common stock, $0.01 par value, 100,000,000 shares authorized, 6,794,395 and 3,456,000 shares issued and outstanding as of March 31, 2025 and June 30, 2024, respectively			67,941				34,557
Treasury stock, at cost, 116 shares as of March 31, 2025 and June 30, 2024, respectively			(1	)			(1	)
Additional paid-in capital			65,012,004				60,971,740
Accumulated deficit			(59,442,961	)			(51,964,332	)
Accumulated other comprehensive loss			(523,417	)			(712,614	)
Total consolidated Intelligent Bio Solutions Inc. equity			5,113,566				8,329,350
Non-controlling interest			(169,800	)			(146,159	)
Total shareholders’ equity			4,943,766				8,183,191
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		$	9,584,527			$	13,778,863

Intelligent Bio Solutions Inc.
Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)
(Unaudited)
(Amount in US$)

		Three months ended March 31,								Nine months ended March 31,
		2025				2024				2025				2024
Revenue		$	728,867			$	823,800			$	2,208,648			$	2,383,957
Cost of revenue (exclusive of amortization shown separately below)			(387,499	)			(645,311	)			(1,297,366	)			(1,773,889	)
Gross profit			341,368				178,489				911,282				610,068
Other income
Government support income			173,271				83,842				433,039				346,917
Operating expenses
Selling, general and administrative expenses			(2,407,558	)			(2,425,830	)			(6,165,688	)			(6,587,934	)
Development and regulatory approval expenses			(358,351	)			(471,313	)			(1,814,047	)			(923,712	)
Depreciation and amortization			(301,978	)			(318,923	)			(907,577	)			(916,796	)
Total operating expenses			(3,067,887	)			(3,216,066	)			(8,887,312	)			(8,428,442	)
Loss from operations			(2,553,248	)			(2,953,735	)			(7,542,991	)			(7,471,457	)
Other income (expense), net
Interest expense			(15,000	)			(42,674	)			(50,829	)			(112,590	)
Realized foreign exchange loss			(113	)			(996	)			(914	)			(1,551	)
Fair value gain on revaluation of financial instrument			-				-				-				175,738
Interest income			17,687				10,640				92,464				14,288
Total other income, net			2,574				(33,030	)			40,721				75,885
Net loss			(2,550,674	)			(2,986,765	)			(7,502,270	)			(7,395,572	)
Net loss attributable to non-controlling interest			(7,148	)			(9,098	)			(23,641	)			(23,060	)
Net loss attributable to Intelligent Bio Solutions Inc.		$	(2,543,526	)		$	(2,977,667	)		$	(7,478,629	)		$	(7,372,512	)
Other comprehensive income (loss), net of tax
Foreign currency translation gain (loss)			116,007				(144,026	)			189,197				(86,909	)
Total other comprehensive income (loss)			116,007				(144,026	)			189,197				(86,909	)
Comprehensive loss			(2,434,667	)			(3,130,791	)			(7,313,073	)			(7,482,481	)
Comprehensive loss attributable to non-controlling interest			(7,148	)			(9,098	)			(23,641	)			(23,060	)
Comprehensive loss attributable to Intelligent Bio Solutions Inc.			(2,427,519	)			(3,121,693	)			(7,289,432	)			(7,459,421	)
Net loss per share, basic and diluted		$	(0.44	)		$	(1.43	)		$	(1.59	)		$	(6.64	)
Weighted average shares outstanding, basic and diluted			5,771,911				2,079,864				4,698,494				1,110,089

FAQ

What was INBS's revenue growth in Q3 2025?

INBS reported a 20% sequential quarterly revenue growth, reaching $0.73 million in Q3 2025.

How much did INBS's cartridge sales contribute to total revenue in fiscal 2025?

Cartridge sales represented 58% of total revenue for the nine months ended March 31, 2025, increasing from 49% in the same period of 2024.

What was INBS's cash position as of March 31, 2025?

INBS reported total cash and cash equivalents of $2.81 million as of March 31, 2025.

How many new accounts did INBS add in Q3 2025?

INBS added 35 new accounts during Q3 2025, bringing their total active account base to over 450.

What was INBS's net loss for Q3 2025?

INBS reported a net loss of $2.54 million for Q3 2025, which was an improvement of $434,141 compared to the same period in 2024.